Using Ubiquitin Binders to Decipher the Ubiquitin Code

Michael Mattern, James Sutherland, Karteek Kadimisetty, Rosa Barrio,
Manuel S. Rodríguez

► To cite this version:

Michael Mattern, James Sutherland, Karteek Kadimisetty, Rosa Barrio, Manuel S. Rodríguez. Using Ubiquitin Binders to Decipher the Ubiquitin Code. Trends in Biochemical Sciences, 2019, 44 (7), pp.599-615. 10.1016/j.tibs.2019.01.011 . hal-02351181

HAL Id: hal-02351181

<https://hal.science/hal-02351181>

Submitted on 25 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International License

Using Ubiquitin binders to decipher the Ubiquitin Code

Michael Mattern^{1#}, James Sutherland^{2#}, Karteek Kadimisetty³, Rosa Barrio², Manuel S. Rodriguez^{4*}

¹Progenra Inc., 277 Great Valley Parkway, Malvern 19355, Pennsylvania, USA

²CIC bioGUNE, Technology Park of Bizkaia, Bldg. 801A, 48160 Derio, Spain

³LifeSensors Inc., 271 Great Valley Parkway, Malvern 19355, Pennsylvania, USA

⁴ITAV-IPBS-UPS CNRS USR3505, 1 place Pierre Potier, Oncopole entrée B, 31106 Toulouse, France

Equal contribution

*Corresponding author: Manuel.RODRIGUEZ@itav.fr

Keywords:

Ubiquitin-code

UBDs

TUBEs

Affimers

Proteolysis

Signaling

UPS

ALS

Abstract

Post-translational modifications (PTMs) by ubiquitin (Ub) are versatile, highly dynamic, and involved in nearly all aspects of eukaryote biological function. The reversibility and heterogeneity of Ub chains attached to protein substrates have complicated their isolation, quantification, and characterization. Strategies have emerged to isolate endogenous ubiquitylated targets, including technologies based on the use of Ub-binding peptides, such as TUBEs (Tandem-repeated Ubiquitin-Binding Entities). TUBEs allow the identification and characterization of ubiquitin chains, novel substrates for deubiquitylases (DUBs) and Ub ligases (E3s). Here we review their impact on purification, analysis of pan or chain-selective polyubiquitylated proteins and underline the biological relevance of this information. Together with peptide aptamers and other Ub affinity-based approaches, TUBEs will contribute to unravelling the secrets of the Ub-code.

The Complexity of the Ubiquitin Code

Ubiquitination of proteins is a significant regulatory process that affects almost all cellular functions. Ubiquitin (Ub) is a small, compact, and highly conserved 76 amino acid protein. The C-terminus of Ub is attached by an isopeptide bond to the ϵ -amino group of lysine residues on target proteins. After Ub is attached to a protein, this proximal Ub can act as a substrate for additional Ubs, which are conjugated to any of its seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) or to its N-terminal methionine (M1) [1]. Protein ubiquitylation was first described as a signal for proteasomal degradation. The so called **Ub-proteasome system (UPS)** (see Glossary) uses mainly K48 and K11 polyubiquitylation as signals for substrate recognition [2, 3]. The 26S proteasome include subunits that contain Ub-binding domains (UBDs) (Box 1) that participate in the binding of ubiquitin chains [4, 5]. The binding and disassembly of many different types of Ub chains vary in both length and linkage specificity [6, 7]. Although the presence of one Ub chain type is not by itself indicative of one function, accumulated evidence supports the existence of certain generic roles. For instance, proteasome inhibition leads to accumulation of ubiquitylated proteins containing all seven different types of Ub linkages except for K63 [8], strongly suggesting that K63 chains do not primarily target proteins to proteasomes. K63 Ub chains drive proteolysis primarily by the **autophagy-lysosome system (ALS)** [2] and might mediate DNA repair and other signaling pathways. Not much is known about the functions and mechanisms of more atypical linkages such Lys6, Lys27, Lys29, Lys33, and Met1 [9]. This Ub chain complexity known as the “Ub-code” includes mono- and multi-mono-Ub modifications, chains mixing multiple Ub linkages and other **Ub-Like molecules (UbL)**. The biological relevance of most of these complex chains remains to be elucidated [10, 11].

The Ub code is dynamically regulated by (i) a specific set of enzymes (E1, E2s, and E3s) to generate the chain (writers); (ii) a set of deubiquitylases (DUBs) that cleave Ub completely from substrates (erasers) or edit the type and linkage of poly-Ub (editors); and (iii) a variety of proteins containing UBDs that recognize the chain type(s) (readers) on the substrate and execute the desired effect (Figure 1). The specificity of the ubiquitylation machinery comes mainly from the E3 ubiquitin ligases, as they participate in the specific recognition of signals present on the target proteins, and the E2 conjugating enzymes which will work only with a limited set of E3 enzymes [12, 13]. However, there are no consensual lysines to attach Ub on target proteins as occurs with other UbLs [12, 13]. Removal of the Ub chains is mediated by ~100 DUBs identified in humans [14]. DUBs have UBDs which help regulate their specificity and activity in distinct signaling events, cellular functions and compartments [15]. Interaction of DUBs with polyUb chains depend on linkage specificity, as shown by structural studies [14, 15].

Protein modification by other UbLs, such as SUMO (Small Ubiquitin-like Modifier), NEDD8 (neural precursor cell expressed, developmentally down-regulated 8), or ISG15 (Interferon-stimulated gene 15), involve specific set of enzymes for conjugation to and deconjugation from substrates [16]. Like Ub, SUMO2/3 paralogs form polymeric chains that are often terminated by SUMO1, which lacks a consensus SUMOylation site [17]. NEDD8 has been shown to form chains *in vitro* [18]. Heterologous Ub/NEDD8 chains are formed in response to stress conditions [10, 19]. SUMO chains are targets of polyubiquitylation [11], and proteomic studies suggest extensive cross-modifications of unknown function among Ub, NEDD8, SUMO and other UbLs [20-22]. Therefore, Ub and UbL modifications function as a signaling system with a complex form of regulation. Like Ub, UbLs are signals interpreted by decoder proteins containing motifs/domains that specifically recognize them (Box 1). The best studied motifs are those interacting with SUMO, known as SUMO-interacting motifs

(SIMs) [23] and ATG8 [24]. Motifs interacting with NEDD8 [25] and other UbLs exist, but additional efforts are required to fully characterize them and understand their roles in driving specific functions. Deciphering the Ub-code has become a priority in research and biomedicine because of its potential to identify specific biomarkers for multiple diseases and new targets for drug development (Box 2).

UBDs recognize diverse Ub chains on specific protein substrates [26]. UBDs described to date recognize a specific patch of hydrophobic residues on one Ub molecule, called the Ile44 patch (L8, I44, and V70) [12, 27]. Structural studies have demonstrated that UBDs selectivity arises from the recognition of a unique orientation of a Ub chain and distinct surfaces on an Ub moiety or through the direct interaction with the linker region connecting two Ub molecules (Box 1) [27]. The required length of Ub chains binding to a UBD is short since di or tri Ub chains bind very efficiently [26]. Individual UBDs were first used to isolate ubiquitylated proteins of interest but their low affinity for Ub chains limited their use as purification tools [28]. More recently, other affinity-based technologies, such as **TUBEs**, **aptamers** and **affimers**, coupled with proteomic analysis, have emerged as promising methods to identify UbL-modified proteins. The crucial roles that Ub/UbL modifications have in diverse cellular processes and the burgeoning interest in Ub/UbL pathways as sources of new drug targets (Box 2), has motivated the continuing development of a broad toolbox for studying UbL-modified proteins.

In this review we will discuss the latest advances on the use of these technologies aiming to illustrate advantages and disadvantages of various applications, so researchers can decide which are the most appropriate for their experiments. We will also highlight how these methods have contributed to evolving fundamental biological concepts and generating translational knowledge.

Methods to Study Protein Modifications by Ub and Ub-Like Proteins

Owing to the central role of Ub/UbL-modifications in proteostasis, the isolation and identification of modified proteins *via* **mass spectrometry (MS)** has become a fundamental step toward understanding cellular processes and disease. However, this presents difficulties as the proportion of modified *versus* the total pool of a given protein is usually low, modifications being transient and sensitive to the action of DUBs. Nonetheless, a number of techniques have been developed to overcome these obstacles (Figure 2A).

Expression of Tagged-Ub and Ub-like proteins

Among the most common methodologies is the use of tagged forms of Ub and UbLs. Poly-histidine tagged (His)-Ub and UbLs have been used frequently for MS in cultured cells and model organisms (e.g. [28, 29]). The isolation of His-Ub by nickel affinity chromatography can be performed under denaturing conditions, protecting targets from the action of DUBs, but background can be expected from proteins containing natural His-stretches. Alternatively, a short peptide (AviTag) that can be biotinylated by the enzyme BirA can be used as a tag. Biotin-streptavidin interaction allows denaturing purification procedures in cultured cells and transgenic animals [30-33]. Background from a small number of endogenously biotinylated proteins can be expected. Other epitope tags such as Myc, Hemagglutinin (HA), FLAG, Glutathione S-transferase (GST) or Green Fluorescent Protein (GFP), require immunoprecipitation under mild conditions, leading to the isolation of non-covalent interactors as well as modified substrates (Figure 2A). To increase the purity of the samples, two different tags following two sequential purification steps can be used [34],

although the increased size of the tag can potentially interfere with conjugation/deconjugation rates.

One advantage of tagged-UbLs is that they can be easily modified for specific goals, for example, mutations can be introduced to optimize MS identification [35, 36] or to prevent formation of certain chain types [37, 38]. In addition, UbL-modified proteins can be captured in a tissue- or temporal-specific manner in genetically tractable organisms [31, 33, 39]. One disadvantage is the need for exogenous expression by transfection or transgenesis, which might alter cellular dynamics. This can be minimized by generating stable transformants with low expression levels or fusing the tag endogenously by genetic manipulation [29]. Notably, the need for transgenesis and overexpression for tagged-UbLs largely precludes their use with human patient-derived tissues, which is especially relevant in the study of pathologies.

Antibody-Based Strategies

Monoclonal antibodies have been developed that recognize the C-terminal di-Gly motif of Ub that remains attached to target lysines after digestion with trypsin, facilitating purification of these branched peptides (also known as Ub signatures) and identification by MS (**Figure 2A**) [22]. However, other UbLs (NEDD8, ISG15) also leave a di-Gly signature on their target peptides, complicating the analysis. To avoid this, UbiSite antibodies have been recently developed, which recognize a longer Ub-specific branched peptide generated by digestion with LysC [21]. Antibodies have also been developed that recognize specifically the signatures by SUMO1 and SUMO2/3 [40, 41], or M1-, K48-, and K63-linkage-specific Ub chains [42-46]. Advantages include the use of almost any starting material and, of particular importance, the analysis of endogenously modified proteins. However, conditions for capture may not solubilize all potential targets and non-modified, co-purifying proteins may lead to background. Moreover, larger amounts of starting material may be necessary, and antibodies

can be costly. These reasons motivated the development of alternative procedures to explore Ub-linkage specific functions.

Approaches Based on Ub/UbL-Binding Peptides to Study Protein Modifications

Molecular Traps Based on Ub/UbL-Binding Domains

Another interesting technology recently developed is the use of peptides or small proteins that interact with single or various Ub/UbL chain types (See Box 1 for the description of different UBDs and SIMs). The relatively weak binding affinities of individual UBDs for Ub, with K_d values in the micromolar range [28], suggest that cells employ a multivalent binding mechanism that would facilitate dynamic and transient interactions with multiple Ub moieties to execute activities linked to poly-Ub signaling. Beyond the Ub-UBD interaction, binding of ubiquitylated proteins and their receptors likely involves conformational changes, non-UBD sequences, specificity for a particular linkage, and increased avidity due to either protein oligomerization or the existence of multiple Ub-binding surfaces in single UBDs (Box 1, Table I) [47-49].

Considering their specificity for poly-Ub, UBDs can be used in affinity purification of poly-ubiquitylated proteins. Initial attempts involved full-length Ub-binding proteins. For example, a GST-tagged full-length human S5a (containing two tandem Ubiquitin Interacting Motifs, UIMs) has been employed to enrich the ubiquitylated proteins from brain and placental tissue [50]. Similarly, the Ub-binding properties of Rad23 and Dsk2 have been utilized to screen the substrates of the 26S proteasome in budding yeast [51]. UBDs have been also used to develop Ub ligase substrate trapping, a technique that fuse UBDs to an E3 ligase to purify and identify by MS ubiquitylated substrates of a particular E3 ligase [52].

A significant improvement was the multimerization of UBDs coming from various proteins, as is the case for TUBEs (Tandem-repeated Ubiquitin-Binding Entities) [53, 54]. TUBEs consist of tetramerized Ubiquitin Associated (UBA) domains from the proteins UBQLN1 (TUBE1) or HR23A (TUBE2) separated by flexible linkers and fused to multiple tags to facilitate purification and detection (Figure 2A) [53]. TUBEs bind preferentially to polyubiquitylated proteins, with affinities in the low nanomolar K_d range, which approximates that of a very good antibody underlining its potential as a purification tool. It has also been demonstrated that TUBEs binding shields the poly-Ub chains from DUB cleavage and from proteasome recognition and degradation [53].

While TUBEs display a preference for poly-Ub chains, they can also be used to isolate highly abundant mono- or multiple mono-ubiquitylated substrates. For example, it was found that multiple mono-ubiquitylated p53 is accumulated in response to chemotherapy [53, 55] and a mono-ubiquitylated pool of I κ B α resistant to TNF α -mediated degradation plays a role in the regulation of basal NF- κ B signaling [56].

Since some UBDs show preference for certain linkages, TUBES can be designed to capture substrates enriched in particular linkage types. In an illustrative example, a K63-selective TUBE was used to enrich K63-linked polyubiquitylated proteins and analyze their role in oxidative stress response by MS-based proteomics [57].

As for Ub, similar tandem affinity binding entities have been designed for other UbLs, including SUMO. The four SUMO-Interacting Motifs (SIMs) from the SUMO-dependent E3 ligase RNF4 were used to isolate and identify 300 polySUMO conjugates from cultured eukaryotic cells [58]. Similar to TUBEs, SUMO binding entities, or **SUBEs**, have been developed [59-61]. SUBEs include four each of SIM2 and SIM3 motifs from RNF4 disposed in tandem (8 SIMs in total) fused to a GST or Biotin tag. They specifically interact with polySUMO chains and do not bind to poly-Ub chains or free SUMO moieties [59]. Creating

new tools to isolate substrates modified by heterologous or hybrid Ub-UbL chains would perhaps reveal processes regulated in this manner [62].

Other Binding Strategies

In addition to the strategies based on existing Ub/UbL-binding domains, other approaches based on novel binding proteins are capable of isolating endogenous conjugates (Figure 2A and Box 3). Peptide aptamers, such as affimers, adnectins (also known as monobodies), and darpins are characterized by small size, a stable folding core domain, and variable domains or peptide loops that can be randomized. Likewise, camelid-derived nanobodies can be derived from *in vivo* sources by immunization or synthetic design. Large libraries can be generated and screened using display and panning methods (using ribosomes, phage or yeast) [63]. Affimers have been described that discriminate K6 or K33/K11 di-Ub linkages [64]. These tools can be used in a variety of applications including MS studies to identify specific targets of these modifications [64, 65]. Aptamer technology can also identify binders that inhibit Ub/UbL pathways [66-68]. Nanobodies can be used for targeted degradation via E3 ligase fusion or recruitment [69, 70] (Figure 2A and Box 3).

To date, most published studies use the UBD-based molecular traps, so we now provide more detailed examples of their use in research and in the clinic.

Applications for TUBEs

TUBEs and other molecular traps such as SUBEs, alone or in combination with other techniques (Figure 2B), have been used for a wide variety of applications (Figure 3, Key Figure). We highlight here some of their published uses.

Study of the Ubiquitylation of Specific Proteins

TUBEs are most commonly used as affinity purification reagents for polyubiquitylated proteins. GST or biotinylated TUBEs can be conjugated either to solid supports such as agarose or magnetic beads for affinity purification or be included during the lysis and used as capture reagents. K63-selective TUBEs have been used to show that Parkin-derived K63-Ub chains are dispensable for mitophagy, that ubiquitylation of CENP-A^{CNP1} prevents the formation of ectopic centromeres, and that the androgen receptor is a target of the E3 ligase CHIP [71-73]. TUBE2 which is based in the UBA domain of the UV excision repair protein HR23A has been used to demonstrate the role of Ub in multiple types of stress, including chemotherapy [74, 55]. Pan-specific TUBEs have been used to show that Rac1 is ubiquitylated by the HECT E3 Hace1 [74, 75], and to discriminate the ubiquitylation pattern of cells that are sensitive or resistant to doxorubicin chemotherapy, underlining the potential use of TUBEs in the search for biomarkers [55, 74, 75].

Ub-mediated degradation of essential enzymes may have particular importance in the central nervous system. Using TUBEs, it was shown that Ub carboxy-terminal hydrolase 1 (UCHL1) antagonizes ubiquitylation of choline transporter (CHT) in a cholinergic neuron model [76]. While K48-linked polyubiquitylation is typically considered to target proteins for degradation, TUBEs identified noncanonical Ub-dependent degradation mechanisms, as K63-linked HIF1A ubiquitylation signaling degradation by the ALS, expanding the known roles of Ub in intracellular proteolysis [77]. TUBEs were also associated with immunoprecipitation protocols (TUBE-IP) to identify ubiquitylated forms of IκBα or p53 [74, 78]. In this way K63-TUBEs were also used to show the timing of RIPK2 ubiquitylation in NOD2 signaling [79]. Thus, TUBE-IP can be used to investigate kinetics of Ub chain formation or remodeling in response to multiple stimuli.

Mass Spectrometry Identification

As mentioned, TUBEs protect Ub-chains from degradation. By performing TUBEs-based isolation under native conditions, it is also possible to preserve interactors and complexes built around ubiquitylated proteins, such as the proteasome in an example from adriamycin-treated MCF7 cells [74, 80]. MS analysis of TUBEs-enriched extracts identified a unique interplay between the human host and the UPS of *Plasmodium falciparum* over the course of malaria infection [81]. In addition, whole-proteome methods utilizing TUBEs revealed novel roles of K63 polyubiquitylation in oxidative stress response in *Saccharomyces cerevisiae* (Figure 3) [57, 82].

Comparative proteomics studies show the utility of TUBEs for complementary MS studies. For instance, when using stable isotope labeling with amino acids in cell culture (SILAC) to study the effects of Ndfip1/Ndfip2 knockout in mouse CD4⁺ T cells, biotin-TUBE enrichment yielded higher numbers of identified proteins compared with the di-Gly antibody [83]. The combined use of both technologies significantly increased the identified number of di-Gly peptides when a specific F-box protein (FBXO21) was overexpressed (Figure 2B) [84].

Detection Methods

Given their specificity, TUBEs have been used in place of antibodies to detect ubiquitylated proteins. Distinct applications have been implemented with distinct tagged versions of non-selective TUBEs. For instance, TUBEs labelled with fluorescent tags can be used in co-localization experiments in combination with antibodies recognizing specific Ub-target proteins (Figure 3) [85]. One innovative example is a method for studying inflammasome formation in relation to Ub modification of NLRP3 (nucleotide-binding oligomerization domain-like receptor P3) [86]. Chain-selective TUBEs can similarly be used

in **far-Western immunoblots**. For instance, use of the biotin-labeled K63-TUBE revealed K63-polyubiquitylation of PINK1 kinase by the E3 ligase TRAF6 [87].

High-Throughput Screens, Arrays and Drug Discovery

TUBEs have been incorporated into high-throughput screens (HTS) for monitoring E3 ligase and DUB activities. Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET)-based assays monitor autoubiquitylation of E3s, in which biotinylated TUBE is labeled with acceptor fluorophore while E3 antibody is labeled with donor fluorophore [88]. Examples include the characterization of Ndfip-dependent activation of Nedd4-family HECT E3 ligases and the ubiquitylation of GFP-fused I κ B α [89, 90]. In similar assays, TUBE and an antibody against an E3 ligase have been linked to donor and acceptor beads, respectively, showing their co-localization upon E3 ligase autoubiquitylation (Figure 2B) [91].

TUBEs have been applied to monitor total cellular Ub in an enzyme-linked immunosorbent assay (ELISA) format, for instance in AlphaLISA or dissociation-enhanced lanthanide fluorescent immunoassay (DELFI) variations [81, 92]. Multiple detection systems and formats can be configured using multi-well plates to search for biomarkers. For those cases wherein the amount of starting material is an issue, TUBEs-based protein arrays have been designed, for example, to detect changes in total protein ubiquitylation after treatment with doxorubicin (Figure 2B) [74, 93].

TUBEs can also be used to assist in qualitative assessment of ubiquitylation. To develop USP7 inhibitors, an assay comprised of TUBE enrichment of ubiquitylated proteins, followed by their elution and treatment with or without a broad-spectrum DUB was used [94]. In this way the effects of USP7 inhibitor treatment on Tip60 and FoxP3 ubiquitylation in mouse T-regulatory cells were demonstrated [94]. This approach was further adapted using chain-linkage specific DUBs OTUB1 (K48-specific) and AMSH (K63-specific) to

demonstrate that USP7 is modified predominantly by K48-linked poly-Ub chains [95]. These applications of TUBEs validated USP7 inhibitor P217564 in cells and enabled advancement of this compound towards *in vivo* animal model studies.

Limitations and Challenges for Ub/UbL-Binding Based Approaches

While TUBEs have a number of advantages over other technologies, there are limitations. Development of new TUBES can be challenging and, although screening for Ub/UbL-binding elements can be performed in an unbiased, high-throughput manner, the validation steps require considerable planning and effort.

Most TUBEs recognize poly-Ub chains and isolation of low abundant mono-ubiquitylated proteins is still challenging. Since 50% of conjugated Ub exists in the mono-ubiquitylated state [96, 97], a priority is to develop a molecular trap or affinity binders that can selectively identify a single conjugated Ub/UbL or even specific mono-ubiquitylated substrates. This has been achieved by traditional antibody methods (e.g., mono-ubiquitylated histones [98]).

Ub chains exist in branched and heterotypic forms comprised of Ub and UbLs. TUBEs have not been extensively evaluated for specific binding in these scenarios, while at least one antibody shows specificity for branched chains [99]. The chimeric K11/K48 antibody employs variable regions from K11- and K48-specific antibodies.

Most TUBEs variants were first tested *in vitro* to analyze their specificity and affinity for distinct chain types. Chain composition *in vivo*, however, is more complex than initially suspected [62], questioning whether chains containing only a single type of linkage would be a general feature or an exception. It is therefore likely that even linkage-specific TUBEs will

capture a small percentage of other linkage types. Moreover, correct titration is important, since it has been observed that an excess of K63-specific TUBEs can allow weak binding to K48-linked poly-Ub [100]. Likewise, saturating a solid support such as a plate surface or an agarose bead with chain-selective TUBE may lead to poor selectivity, perhaps due to high density or avidity effects. Optimization is often required and recommended. Furthermore, some data support the notion that TUBEs may have affinity for heterotypic chains containing other UbL proteins [78, 101], but better characterization is needed since these are stimulus-dependent events.

For imaging and cellular applications, TUBEs must be introduced into cells by protein transduction or transfection of expression constructs [84, 85]. Cellular overexpression of TUBEs could result in aberrant effects, due to the inherent ability of TUBEs to interfere with the action of DUBs and proteasomal degradation, so inducibility or titration is recommended.

Regarding the combined use of TUBEs with diGly-specific antibodies, some studies suggest that incompatibilities may exist [80, 81], but in some cases the combination of both technologies has provided better results for the detection of Ub signatures [83, 84].

Concluding Remarks and Future Perspectives

Ub/UbL-binding based strategies can greatly contribute to improving our knowledge of the role of these modifications in molecular and cellular processes. A wider panel of tools to enrich Ub/UbL chain types would help in studying their respective biological roles. For example, K6-specific TUBEs will be helpful to identify the individual proteins modified during various selective autophagy events. Little is known about the biological roles of K27-, K29-, and K33-linked poly-Ub chains, so isolating substrates and interactors of these rare Ub

linkages may provide insight into their functions (see Outstanding Questions). The unique properties of TUBEs to protect ubiquitylated proteins from degradation will certainly help to increase the purification yield and detection of scarce ubiquitylated proteins by MS. Custom aptamers, alone or in combination with UBDs, may generate new molecular traps with increased affinity or new specificities. The reduced protein size of aptamers might be advantageous for some applications.

Novel TUBEs and TUBEs-based assays are currently under development. The full potential of TUBEs has yet to be applied to fluorescence-based techniques such as flow cytometry/fluorescence activated cell sorting (FACS) and various types of microscopy to study the direct localization of Ub chains or their interactions by FRET inside live, fixed or permeabilized cell and tissue samples.

The progression of UPS-targeted drugs to the clinic will require a battery of assays to validate these compounds and TUBEs are well-suited owing to their adaptability to HTS formats. Moreover, TUBEs can be adapted for the discovery of diagnostic markers and drug targets by targeted or global MS studies of differential protein ubiquitylation in disease. Their use to monitor ubiquitylation of downstream substrates of DUBs and E3 ligases will be particularly important for determining the efficacy of potential drugs for these emerging target classes. In summary, TUBEs and other Ub binders will certainly continue to play a role in Ub drug discovery.

Acknowledgements

We thank Dominic Vasturia and Yogesh Kulathu for their scientific input and help with the structural figures. We also thank Gregoire Quinet and Niels Riechardt for the use of original fluorescence and microarray figures. RB, JS and MSR are part of the UbiCODE project and received funding from the European Union's Horizon 2020 research and innovation program

under the Marie Skłodowska-Curie grant agreement No 765445. MSR is also funded by the Institut National du Cancer, France (PLBIO16-251), the REPERE program of Occitanie, France, LASSERLAB-EUROPE grant number 654148 and CONACyT-SRE (Mexico) grant 0280365. RB and JS acknowledge support from BFU2017-84653-P (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), and SAF2017-90900-REDT (UBIRed Network of Excellence, MINECO).

Glossary

Affimers: Small engineered non-antibody binding proteins designed to mimic the molecular recognition of monoclonal antibodies in various applications.

Aptamers: Peptides or oligonucleotides with binding specificity for a target protein.

Autophagy-lysosomal system (ALS): includes all cellular factors implicated in the regulation of the formation of autophagosomes, fusion with the lysosomes and proteolytic enzymes.

Far-Western immunoblot: This technique uses a non-antibody protein that binds the protein of interest. Thus, it is suitable to detect protein/protein interactions.

Mass spectrometry (MS): analysis is used to quantify Ub and UbL peptide signatures

Post-translational modifications (PTMs): can be chemical changes like phosphorylation or acetylation, but also small peptide modifier such as UbLs.

SUMO Binding Entities (SUBEs): are based on the multiplication of SUMO-Interactive motifs (SIMs) or the SUMO-dependent ubiquitin ligase RNF4.

Tandem Ubiquitin Binding Entities (TUBEs): have multiple binding domains to increase the affinity for ubiquitylated proteins

Ubiquitin-like proteins (UbLs): members of the Ub family presenting the β -grasp fold and the C-terminal double glycine that allows its conjugation to target amino-acid residues.

Ubiquitin Proteasome System (UPS): includes all enzymes and cofactors implicated in protein ubiquitylation and the proteasome.

BOX 1: Ubiquitin Family Proteins-Binding Domains

Ubiquitylated substrates are recognized by effector proteins that usually contain at least one ubiquitin (Ub)-binding domain (UBD) (Figure IA-C). Recent reviews on UBDs discuss their structural characteristics and how they interact with Ub [26, 102, 103]. About 20 different families of UBDs have been described so far and are summarized in Table I. Although these UBDs are structurally quite different, they bind distinct hydrophobic patches contributing to the specificity of the UBDs [26, 102]. These UBDs have been grouped according to their diverse underlying structural features. UBDs have been characterized that are composed of single or multiple alpha-helices, zinc finger motifs, or pleckstrin-homology domains, each class with multiple members. Another UBD type shares structural similarity to E2 conjugating enzymes, but lacks catalytic activity. A final diverse group of UBDs contains other structural elements (coiled-coil motifs, helix-turn-helix, beta sheets, SH3). The existence of multiple UBDs is justified by the chain structure diversity and complexity. For instance, K48-, K11-, K33 and K6-linkages adopt a compact “closed” conformation where the hydrophobic patches are buried [104, 105], while M1, K29 and K63-poly-Ub chains adopt an extended “open” conformation where hydrophobic patches are accessible and contribute to binding [106]. Further, some binding domains recognize surfaces on two adjacent Ub molecules, conferring chain specificity and producing a cooperative increase in affinity (Figure IA-C) [107-109].

Substrates modified by SUMO molecules are also recognized by effector proteins containing motifs that specifically recognize substrates modified by SUMO1, SUMO2 and SUMO3. Recent reviews on SUMO-interacting motifs (SIMs), and how these interact with SUMO molecules, have addressed structural and biological relevant aspects (Figure ID) [11, 110, 111]. At least 3 types of hydrophobic SIMs contribute to the coordination of SUMO-dependent functions (Figure IE). Typically, SIMs are constituted by a hydrophobic core flanked by one or two clusters of negatively charged amino acid residues [112]. Several SIMs can integrate SUMO binding domains (SBDs), optimizing binding, and improving control over processes regulated by protein SUMOylation. Multiple methodologies exploring biochemical, cellular and molecular aspects of protein SUMOylation have been developed to better understand the role of SIMs in SUMO-regulated processes [61, 113-115].

Table I. Ubiquitin-binding domains (UBDs)

UBD structural class	UBD examples (abbreviations)	Representative proteins	Refs
Alpha-helical	UBA	RAD23, DSK2	[116, 117]
	CUE	Vps9	[118, 119]
	UIM	S5a, RAP80, EPS15	[120-123]
	MIU/IUIM	Rabex5	[124]
	DUIM	Hrs	[125]
	VHS	STAM	[126]

	GAT	GGA3, TOM1	[127-129]
Zinc-finger	NZF	Npl4	[130], HOIP
	ZnF-A20	A20, Rabex-5	A20, [124]
	ZnF-UBP	USP5, HDAC6	[131, 132]
	UBZ	Polymerase eta/Rad18	[133, 134]
Pleckstrin-homology	PRU	Rpn13	[135]
	GLUE	EAP45	[136, 137]
Ub-conjugation-related	UEV	VPS23, TSG101	[138, 139]
Diverse fold class	Jab1/MPN	Prp8p	[140]
	PFU	Doa1/PLAA	[141]
	SH3(variant)	CIN85, amphiphysin	[142, 143]
	UBAN	NEMO, optineurin	[144]

Figure I: Binding domains interacting with poly-Ub chains and SUMO. Ubiquitin (Ub)

Binding Domains, UBDs, are very diverse domains that are able to distinguish different Ub chain-linkages. The binding mechanism depends on the structure of each domain and amino acid composition of each UBDs. (A) The MIU motif of MINDY1 (blue) has three distinct Ub interaction sites that enable it to bind to K48-linked polyubiquitin (sand/yellow) (PDB: 5MN9). (B) The NZF domain of TAB2 (blue) binds to K63-linked polyubiquitin (cyan/teal) (PDB: 2WWZ). (C) The NZF domain of TRABID (blue) binds to K29-linked polyubiquitin (pink/violet) (4S1Z). (D) Solution structure of SUMO interacting motif bound to SUMO.

Cartoon representation of the complex between SUMO1 (pink) and SUMO interacting motif (SIM) peptide (blue) from the M-IR2 region of RanBP2 (PDB 2LAS). (E) SIMs domains in PROSITE format [112].

BOX 2: Druggability of the Ubiquitin System

Given the parallel between the ubiquitin (Ub) and Ub-Like (Ub/UbL) regulation and other post-translational modifications (PTMs), such as phosphorylation, the Ub Proteasome System (UPS) became an obvious target for developing drugs having an impact on its regulatory enzymes. For this reason, it was somehow surprising that the first drug developed targeted a catalytic subunit of the proteasome, previously thought to be a conserved part of the UPS and thus not a selective target for drug development. Currently, the proteasomal inhibitors Bortezomib and Carfilzomib are prescribed as first line therapies for drug refractory multiple myeloma [145], garnering ~\$17 billion per year. These impressive numbers heightened pharmaceutical interest in Ub/UbL pathways. Deubiquitylases (DUBs) and E3 ligases have always been recognized as prime targets from which to develop selective therapies. The only E3 ligase drugs presently marketed, however, are thalidomide and its derivatives (called immunomodulatory imides or IMiDS), being prescribed for multiple myeloma and mantle cell lymphomas [146]. The IMiDS bind cereblon, the substrate binding subunit of cullin ligase, and modulate E3 ligase function [147]. This results in ubiquitylation of Ikaros and other C2H2 zinc finger transcription factors (as well as other beta loop containing degrons) and activation of antitumor responses by the immune system [148, 149]. Thalidomide was previously used for treating morning sickness in pregnant mothers, but tragically resulted in eye, heart, and especially limb defects among many children. Only recently the transcription factor SALL4 was identified as a likely target for thalidomide in causing these birth defects [150, 151].

This example highlights a critical bottleneck in developing drugs that focus on DUBs and Ub ligases – the ability to comprehensively identify targets of their activity to avoid deleterious off-target effects. If this knowledge is available, more thorough screenings can lead to improved drug candidates. A better characterization of molecular mechanisms underlying Ub-mediated regulation will be essential to progress in this area.

BOX 3: Tools Recognizing Ub Chain Diversity

Multiple tools have been developed to isolate and/or identify individual ubiquitin (Ub) chain types. The specificity and applications of these tools could be very distinct; however, redundancy might exist and parallel comparisons under the same conditions are lacking in most of the cases. In many scenarios, these tools are complementary and can be used to avoid cross-reactions (e.g., between antibodies) or to unravel a higher level of molecular complexity as soon as it is verified that the binding sites are not competing with each other. In many cases, and depending of the nature of the interaction, tools containing multiple binding domains (such as TUBEs) have higher affinity for Ub chains than those having single binding sites. In Table I chains recognized by each tool are indicated, including the names of the tools and the name of distributors or references associated to them.

Table I. Specific binding tools for ubiquitin chain diversity

Tool	Linkage recognition	Name (s)	Distributor	Refs
Antibodies	M1	LUB9/1E3	Sigma, Millipore	[152]
	K11	2A3/2E6	Sigma, Millipore	

	K27 K48 K63 Mono- & Poly-Ub PolyUb	EPR17034 EP8589, 4289, Apu2 EPR8590-448, D7A11, Apu3, HWA4C4. FK2 FK1	Abcam Abcam, Cell Signaling, Millipore Abcam, Cell Signaling, Millipore, Thermo Fisher Millipore Millipore	
TUBEs	All chains K63 K48	TUBE1, TUBE2 TUBEK63 TUBEK48	Lifesensors; Boston Biochem Lifesensors Lifesensors	[53] [153]
SUBEs	PolySUMO2/3	RNF4 based SUMO- affinity matrices SUMO-traps	Boston Biochem, Lifesensors	[58] [59]
Aptamers	K48 K48	Minibodies and Nanobodies	Hybrigenics	[154]
Affimers	K6 K33 SUMO1 SUMO2	Linkage-specific affimers	Avacta	[64]

Figure 1. The complexity of the Ub-code. The elaborated architecture of the ubiquitin (Ub) chains adopting distinct conformations is due to the integration of multiple Ub linkages, such as the Ub-like molecules Small Ubiquitin-like Modifier, SUMO (SU), or neural precursor cell expressed, developmentally down-regulated 8, NEDD8 (N8), but also other PTMs including phosphorylation (P) and acetylation (A). Those modifications might respond to specific stimuli or stress. The formation of highly dynamic Ub and Ub-like chains is regulated by modifying (Writers: E1 activating, E2 conjugating and E3 ligase enzymes for Ub family members) and de-modifying (Editors/Erasers: Deubiquitylases or DUBs, SUMO-specific proteases and isopeptidases or SENPs, NEDD8 Proteases or NEDPs) enzymes that are specific for each modification. The resultant chains are recognized by receptor proteins connecting with effector functions (Readers: Ubiquitin Binding Domains or UBDs, Ubiquitin Interacting Motifs or UIMs, SUMO interacting motifs or SIMs). Chain remodeling occurs after cell activation in response to distinct physiologic or pathologic events.

Figure 2. Methods to purify ubiquitylated proteins for study by mass spectrometry. (A). Multiple strategies have been developed to identify ubiquitylated proteins by mass spectrometry. Tagged versions of ubiquitin (Ub) or Ub-Like proteins (UbLs) have been extensively used in proteomic studies. Some of the most popular tags include poly-histidine (His), AviTag, Myc, Hemagglutinin (HA), FLAG, Glutathione S-transferase (GST), Green Fluorescent Protein (GFP), or Tandem Affinity Purification with more than one tag (TAP) (left panel). Antibodies against the di-Gly signature recognizing various Ub family members or specific antibodies for UbLs are among the most used (middle panel). Binding tools of different nature based in small proteins/peptides with affinity for Ub or UbLs have been used in distinct proteomic studies (right panel). (B) Tandem Ubiquitin Binding Entities (TUBEs)

can be potentially combined with other technologies to optimize detection of chain-linkages [84]. TUBEs have been successfully used in combination with anti-di-Gly antibodies with very positive results. TUBEs could be combined with peptide affimers (middle panel) or aptamers (lower panel) to improve detection of chain-linkages, although no reports have been published. All these combinations might have advantages and disadvantages that are listed in a non-exhaustive way in this figure.

Figure 3, Key Figure. Applications for TUBEs-based technology. Tandem Ubiquitin Binding Entities (TUBEs) are versatile tools that have been used in multiple applications. These applications include: (A) Detection methods as reagents for Western-blot or florescence, but also to measure binding affinity or specificity (surface plasmon resonance or SPR, calorimetry or thermophoresis). (B) Identification methods when TUBEs are used to affinity purify (pull down) ubiquitylated proteins that can be detected with target-specific antibodies by Western-blot or by mass spectrometry, MS. (C) Quantification of total or individual ubiquitylated proteins and characterization of the functions associated to them using various formats such as protein arrays or High Throughput Screening (HTS) techniques like TUBE-AlphaLISA and TUBE-DELFI (dissociation-enhanced lanthanide fluorescent immunoassay) or to identify specific DUBs for a given substrate (UbiTest assay).

REFERENCES

1. Alfano, C. et al. (2016) The Ball and Chain of Polyubiquitin Structures. *Trends Biochem Sci* 41 (4), 371-385.
2. Kwon, Y.T. and Ciechanover, A. (2017) The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy. *Trends Biochem Sci* 42 (11), 873-886.
3. Meyer, H.J. and Rape, M. (2014) Enhanced protein degradation by branched ubiquitin chains. *Cell* 157 (4), 910-21.
4. Finley, D. et al. (2016) Gates, Channels, and Switches: Elements of the Proteasome Machine. *Trends Biochem Sci* 41 (1), 77-93.
5. Collins, G.A. and Goldberg, A.L. (2017) The Logic of the 26S Proteasome. *Cell* 169 (5), 792-806.

6. Grice, G.L. and Nathan, J.A. (2016) The recognition of ubiquitinated proteins by the proteasome. *Cell Mol Life Sci* 73 (18), 3497-506.
7. Braten, O. et al. (2016) Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. *Proc Natl Acad Sci U S A* 113 (32), E4639-47.
8. Xu, P. et al. (2009) Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. *Cell* 137 (1), 133-45.
9. Akutsu, M. et al. (2016) Ubiquitin chain diversity at a glance. *J Cell Sci* 129 (5), 875-80.
10. Leidecker, O. et al. (2012) The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions. *Cell Cycle* 11 (6), 1142-50.
11. Sriramachandran, A.M. and Dohmen, R.J. (2014) SUMO-targeted ubiquitin ligases. *Biochim Biophys Acta* 1843 (1), 75-85.
12. Wright, J.D. et al. (2016) Noncovalent Ubiquitin Interactions Regulate the Catalytic Activity of Ubiquitin Writers. *Trends Biochem Sci* 41 (11), 924-937.
13. Zheng, N. and Shabek, N. (2017) Ubiquitin Ligases: Structure, Function, and Regulation. *Annu Rev Biochem* 86, 129-157.
14. Leznicki, P. and Kulathu, Y. (2017) Mechanisms of regulation and diversification of deubiquitylating enzyme function. *J Cell Sci* 130 (12), 1997-2006.
15. Mevissen, T.E.T. and Komander, D. (2017) Mechanisms of Deubiquitinase Specificity and Regulation. *Annu Rev Biochem* 86, 159-192.
16. van der Veen, A.G. and Ploegh, H.L. (2012) Ubiquitin-like proteins. *Annu Rev Biochem* 81, 323-57.
17. Vertegaal, A.C. (2007) Small ubiquitin-related modifiers in chains. *Biochem Soc Trans* 35 (Pt 6), 1422-3.
18. Ohki, Y. et al. (2009) The mechanism of poly-NEDD8 chain formation in vitro. *Biochem Biophys Res Commun* 381 (3), 443-7.
19. Maghames, C.M. et al. (2018) NEDDylation promotes nuclear protein aggregation and protects the Ubiquitin Proteasome System upon proteotoxic stress. *Nat Commun* 9 (1), 4376.
20. Hendriks, I.A. et al. (2018) Site-specific characterization of endogenous SUMOylation across species and organs. *Nat Commun* 9 (1), 2456.
21. Akimov, V. et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. *Nat Struct Mol Biol* 25 (7), 631-640.
22. Xu, G. et al. (2010) Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling. *Nat Biotechnol* 28 (8), 868-73.
23. Da Silva-Ferrada, E. et al. (2012) Strategies to Identify Recognition Signals and Targets of SUMOylation. *Biochem Res Int* 2012, 875148.
24. Birgisdottir, A.B. et al. (2013) The LIR motif - crucial for selective autophagy. *J Cell Sci* 126 (Pt 15), 3237-47.
25. He, S. et al. (2017) The Nedd8 Non-covalent Binding Region in the Smurf HECT Domain is Critical to its Ubiquitin Ligase Function. *Sci Rep* 7, 41364.
26. Husnjak, K. and Dikic, I. (2012) Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. *Annu Rev Biochem* 81, 291-322.
27. Fu, Q.S. et al. (2012) Structural aspects of ubiquitin binding specificities. *Curr Protein Pept Sci* 13 (5), 482-9.
28. Hjerpe, R. and Rodriguez, M.S. (2008) Efficient approaches for characterizing ubiquitinated proteins. *Biochem Soc Trans* 36 (Pt 5), 823-7.
29. Tirard, M. et al. (2012) In vivo localization and identification of SUMOylated proteins in the brain of His6-HA-SUMO1 knock-in mice. *Proc Natl Acad Sci U S A* 109 (51), 21122-7.

30. Tagwerker, C. et al. (2006) A tandem affinity tag for two-step purification under fully denaturing conditions: application in ubiquitin profiling and protein complex identification combined with in vivocross-linking. *Mol Cell Proteomics* 5 (4), 737-48.
31. Franco, M. et al. (2011) A novel strategy to isolate ubiquitin conjugates reveals wide role for ubiquitination during neural development. *Mol Cell Proteomics* 10 (5), M110 002188.
32. Lectez, B. et al. (2014) Ubiquitin profiling in liver using a transgenic mouse with biotinylated ubiquitin. *J Proteome Res* 13 (6), 3016-26.
33. Pirone, L. et al. (2017) A comprehensive platform for the analysis of ubiquitin-like protein modifications using in vivo biotinylation. *Sci Rep* 7, 40756.
34. Starokadomskyy, P. and Burstein, E. (2014) Bimolecular affinity purification: a variation of TAP with multiple applications. *Methods Mol Biol* 1177, 193-209.
35. Matic, I. et al. (2010) Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. *Mol Cell* 39 (4), 641-52.
36. Tammsalu, T. et al. (2014) Proteome-wide identification of SUMO2 modification sites. *Sci Signal* 7 (323), rs2.
37. Jung, J.W. et al. (2013) Analysis of the biochemical role of Lys-11 in polyubiquitin chain formation using quantitative mass spectrometry. *Rapid Commun Mass Spectrom* 27 (2), 339-46.
38. Radwan, M. et al. (2015) Protection against murine osteoarthritis by inhibition of the 26S proteasome and lysine-48 linked ubiquitination. *Ann Rheum Dis* 74 (8), 1580-7.
39. Ramirez, J. et al. (2015) Proteomic Analysis of the Ubiquitin Landscape in the Drosophila Embryonic Nervous System and the Adult Photoreceptor Cells. *PLoS One* 10 (10), e0139083.
40. Becker, J. et al. (2013) Detecting endogenous SUMO targets in mammalian cells and tissues. *Nat Struct Mol Biol* 20 (4), 525-31.
41. Barysch, S.V. et al. (2014) Identification and analysis of endogenous SUMO1 and SUMO2/3 targets in mammalian cells and tissues using monoclonal antibodies. *Nat Protoc* 9 (4), 896-909.
42. Newton, K. et al. (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. *Cell* 134 (4), 668-78.
43. Matsumoto, M.L. et al. (2010) K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. *Mol Cell* 39 (3), 477-84.
44. Matsumoto, M.L. et al. (2012) Engineering and structural characterization of a linear polyubiquitin-specific antibody. *J Mol Biol* 418 (3-4), 134-44.
45. Emmerich, C.H. and Cohen, P. (2015) Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting. *Biochem Biophys Res Commun* 466 (1), 1-14.
46. Gilda, J.E. et al. (2015) Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS). *PLoS One* 10 (8), e0135392.
47. Emmerich, C.H. et al. (2013) Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. *Proc Natl Acad Sci U S A* 110 (38), 15247-52.
48. Komander, D. and Rape, M. (2012) The ubiquitin code. *Annu Rev Biochem* 81, 203-29.
49. Trempe, J.F. (2011) Reading the ubiquitin postal code. *Curr Opin Struct Biol* 21 (6), 792-801.
50. Layfield, R. et al. (2001) Purification of poly-ubiquitinated proteins by S5a-affinity chromatography. *Proteomics* 1 (6), 773-7.
51. Mayor, T. and Deshaies, R.J. (2005) Two-step affinity purification of multiubiquitylated proteins from *Saccharomyces cerevisiae*. *Methods Enzymol* 399, 385-92.

52. Mark, K.G. et al. (2016) Isolation of ubiquitinated substrates by tandem affinity purification of E3 ligase-polyubiquitin-binding domain fusions (ligase traps). *Nat Protoc* 11 (2), 291-301.
53. Hjerpe, R. et al. (2009) Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. *EMBO Rep* 10 (11), 1250-8.
54. Lopitz-Otsoa, F. et al. (2010) Properties of natural and artificial proteins displaying multiple ubiquitin-binding domains. *Biochem Soc Trans* 38 (Pt 1), 40-5.
55. Lang, V. et al. (2014) Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. *Mol Oncol* 8 (5), 1026-42.
56. Da Silva-Ferrada, E. et al. (2011) Role of monoubiquitylation on the control of IkappaBalpha degradation and NF-kappaB activity. *PLoS One* 6 (10), e25397.
57. Silva, G.M. and Vogel, C. (2015) Mass spectrometry analysis of K63-ubiquitinated targets in response to oxidative stress. *Data Brief* 4, 130-4.
58. Bruderer, R. et al. (2011) Purification and identification of endogenous polySUMO conjugates. *EMBO Rep* 12 (2), 142-8.
59. Da Silva-Ferrada, E. et al. (2013) Analysis of SUMOylated proteins using SUMO-traps. *Sci Rep* 3, 1690.
60. Lang, V. et al. (2015) Analysis of PTEN ubiquitylation and SUMOylation using molecular traps. *Methods* 77-78, 112-8.
61. Lang, V. et al. (2016) Using Biotinylated SUMO-Traps to Analyze SUMOylated Proteins. *Methods Mol Biol* 1475, 109-21.
62. Nakasone, M.A. et al. (2013) Mixed-linkage ubiquitin chains send mixed messages. *Structure* 21 (5), 727-40.
63. Reverdatto, S. et al. (2015) Peptide aptamers: development and applications. *Curr Top Med Chem* 15 (12), 1082-101.
64. Michel, M.A. et al. (2017) Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling. *Mol Cell* 68 (1), 233-246 e5.
65. Gersch, M. et al. (2017) Mechanism and regulation of the Lys6-selective deubiquitinase USP30. *Nat Struct Mol Biol* 24 (11), 920-930.
66. Hughes, D.J. et al. (2017) Generation of specific inhibitors of SUMO-1- and SUMO-2/3-mediated protein-protein interactions using Affimer (Adhiron) technology. *Sci Signal* 10 (505).
67. Wiechmann, S. et al. (2017) Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation. *J Biol Chem* 292 (37), 15340-15351.
68. Gilbreth, R.N. et al. (2011) Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design. *Proc Natl Acad Sci U S A* 108 (19), 7751-6.
69. Daniel, K. et al. (2018) Conditional control of fluorescent protein degradation by an auxin-dependent nanobody. *Nat Commun* 9 (1), 3297.
70. Shin, Y.J. et al. (2015) Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins. *Sci Rep* 5, 14269.
71. Shiba-Fukushima, K. et al. (2014) Lysine 63-linked polyubiquitination is dispensable for Parkin-mediated mitophagy. *J Biol Chem* 289 (48), 33131-6.
72. Gonzalez, M. et al. (2014) Ectopic centromere nucleation by CENP--a in fission yeast. *Genetics* 198 (4), 1433-46.
73. Sarkar, S. et al. (2014) Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. *Oncogene* 33 (1), 26-33.
74. Lang, V. et al. (2017) Analysis of defective protein ubiquitylation associated to adriamycin resistant cells. *Cell Cycle* 16 (24), 2337-2344.

75. Daugaard, M. et al. (2013) Hsc1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. *Nat Commun* 4, 2180.
76. Hartnett, S. et al. (2014) Ubiquitin C-terminal hydrolase L1 interacts with choline transporter in cholinergic cells. *Neurosci Lett* 564, 115-9.
77. Ferreira, J.V. et al. (2015) K63 linked ubiquitin chain formation is a signal for HIF1A degradation by Chaperone-Mediated Autophagy. *Sci Rep* 5, 10210.
78. Aillet, F. et al. (2012) Heterologous SUMO-2/3-ubiquitin chains optimize I κ B α degradation and NF- κ B activity. *PLoS One* 7 (12), e51672.
79. Damgaard, R.B. et al. (2012) The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. *Mol Cell* 46 (6), 746-58.
80. Lopitz-Otsoa, F. et al. (2012) Integrative analysis of the ubiquitin proteome isolated using Tandem Ubiquitin Binding Entities (TUBEs). *J Proteomics* 75 (10), 2998-3014.
81. Mata-Cantero, L. et al. (2016) New insights into host-parasite ubiquitin proteome dynamics in *P. falciparum* infected red blood cells using a TUBEs-MS approach. *J Proteomics* 139, 45-59.
82. Silva, G.M. et al. (2015) K63 polyubiquitination is a new modulator of the oxidative stress response. *Nat Struct Mol Biol* 22 (2), 116-23.
83. O'Leary, C.E. et al. (2016) Ndfip-mediated degradation of Jak1 tunes cytokine signalling to limit expansion of CD4⁺ effector T cells. *Nat Commun* 7, 11226.
84. Yoshida, Y. et al. (2015) A comprehensive method for detecting ubiquitinated substrates using TR-TUBE. *Proc Natl Acad Sci U S A* 112 (15), 4630-5.
85. van Wijk, S.J. et al. (2012) Fluorescence-based sensors to monitor localization and functions of linear and K63-linked ubiquitin chains in cells. *Mol Cell* 47 (5), 797-809.
86. Palazon-Riquelme, P. and Lopez-Castejon, G. (2016) Method to Measure Ubiquitination of NLRs. *Methods Mol Biol* 1417, 223-9.
87. Murata, H. et al. (2013) SARM1 and TRAF6 bind to and stabilize PINK1 on depolarized mitochondria. *Mol Biol Cell* 24 (18), 2772-84.
88. Marblestone, J.G. et al. (2012) Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins. *Biochim Biophys Acta* 1823 (11), 2094-7.
89. Riling, C. et al. (2015) Itch WW Domains Inhibit Its E3 Ubiquitin Ligase Activity by Blocking E2-E3 Ligase Trans-thiolation. *J Biol Chem* 290 (39), 23875-87.
90. Robers, M.B. et al. (2008) High-throughput cellular assays for regulated posttranslational modifications. *Anal Biochem* 372 (2), 189-97.
91. Schneider, S. et al. (2012) Development of a homogeneous AlphaLISA ubiquitination assay using ubiquitin binding matrices as universal components for the detection of ubiquitinated proteins. *Biochim Biophys Acta* 1823 (11), 2038-45.
92. Mata-Cantero, L. et al. (2015) Development of two novel high-throughput assays to quantify ubiquitylated proteins in cell lysates: application to screening of new anti-malarials. *Malar J* 14, 200.
93. Serna, S. et al. (2016) Efficient monitoring of protein ubiquitylation levels using TUBEs-based microarrays. *FEBS Lett* 590 (16), 2748-56.
94. Wang, L. et al. (2016) Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3⁺ T-regulatory Cell Function and Promotes Antitumor Immunity. *EBioMedicine* 13, 99-112.
95. Wang, F. et al. (2017) Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3⁺ T-regulatory cells by promoting ubiquitination of Tip60. *PLoS One* 12 (12), e0189744.
96. Moyal, L. et al. (2011) Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. *Mol Cell* 41 (5), 529-42.

97. Kravtsova-Ivantsiv, Y. and Ciechanover, A. (2012) Non-canonical ubiquitin-based signals for proteasomal degradation. *J Cell Sci* 125 (Pt 3), 539-48.
98. Vlaming, H. et al. (2016) Direct screening for chromatin status on DNA barcodes in yeast delineates the regulome of H3K79 methylation by Dot1. *Elife* 5.
99. Yau, R.G. et al. (2017) Assembly and Function of Heterotypic Ubiquitin Chains in Cell-Cycle and Protein Quality Control. *Cell* 171 (4), 918-933 e20.
100. Altun, M. et al. (2011) Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. *Chem Biol* 18 (11), 1401-12.
101. Li, J. et al. (2015) NEDD8 Ultimate Buster 1 Long (NUB1L) Protein Suppresses Atypical Neddylation and Promotes the Proteasomal Degradation of Misfolded Proteins. *J Biol Chem* 290 (39), 23850-62.
102. Dikic, I. et al. (2009) Ubiquitin-binding domains - from structures to functions. *Nat Rev Mol Cell Biol* 10 (10), 659-71.
103. Winget, J.M. and Mayor, T. (2010) The diversity of ubiquitin recognition: hot spots and varied specificity. *Mol Cell* 38 (5), 627-35.
104. Castaneda, C.A. et al. (2013) Unique structural, dynamical, and functional properties of k11-linked polyubiquitin chains. *Structure* 21 (7), 1168-81.
105. Virdee, S. et al. (2010) Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. *Nat Chem Biol* 6 (10), 750-7.
106. Weeks, S.D. et al. (2009) Crystal structures of Lys-63-linked tri- and di-ubiquitin reveal a highly extended chain architecture. *Proteins* 77 (4), 753-9.
107. Abdul Rehman, S.A. et al. (2016) MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. *Mol Cell* 63 (1), 146-55.
108. Kulathu, Y. et al. (2009) Two-sided ubiquitin binding explains specificity of the TAB2 NZF domain. *Nat Struct Mol Biol* 16 (12), 1328-30.
109. Kristariyanto, Y.A. et al. (2015) K29-selective ubiquitin binding domain reveals structural basis of specificity and heterotypic nature of k29 polyubiquitin. *Mol Cell* 58 (1), 83-94.
110. Seu, C.S. and Chen, Y. (2009) Identification of SUMO-binding motifs by NMR. *Methods Mol Biol* 497, 121-38.
111. Sahin, U. et al. (2014) PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation. *Nucleus* 5 (6), 499-507.
112. Vogt, B. and Hofmann, K. (2012) Bioinformatical detection of recognition factors for ubiquitin and SUMO. *Methods Mol Biol* 832, 249-61.
113. Matunis, M.J. and Rodriguez, M.S. (2016) Concepts and Methodologies to Study Protein SUMOylation: An Overview. *Methods Mol Biol* 1475, 3-22.
114. Xolalpa, W. et al. (2016) Real-Time Surface Plasmon Resonance (SPR) for the Analysis of Interactions Between SUMO Traps and Mono- or PolySUMO Moieties. *Methods Mol Biol* 1475, 99-107.
115. Husnjak, K. et al. (2016) Identification and Characterization of SUMO-SIM Interactions. *Methods Mol Biol* 1475, 79-98.
116. Bertolaet, B.L. et al. (2001) UBA domains of DNA damage-inducible proteins interact with ubiquitin. *Nat Struct Biol* 8 (5), 417-22.
117. Wilkinson, C.R. et al. (2001) Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. *Nat Cell Biol* 3 (10), 939-43.
118. Donaldson, K.M. et al. (2003) Ubiquitin signals protein trafficking via interaction with a novel ubiquitin binding domain in the membrane fusion regulator, Vps9p. *Curr Biol* 13 (3), 258-62.

119. Shih, S.C. et al. (2003) A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. *EMBO J* 22 (6), 1273-81.
120. Mueller, T.D. and Feigon, J. (2003) Structural determinants for the binding of ubiquitin-like domains to the proteasome. *EMBO J* 22 (18), 4634-45.
121. Swanson, K.A. et al. (2003) Solution structure of Vps27 UIM-ubiquitin complex important for endosomal sorting and receptor downregulation. *EMBO J* 22 (18), 4597-606.
122. Sato, Y. et al. (2009) Structural basis for specific recognition of Lys 63-linked polyubiquitin chains by tandem UIMs of RAP80. *EMBO J* 28 (16), 2461-8.
123. Fisher, R.D. et al. (2003) Structure and ubiquitin binding of the ubiquitin-interacting motif. *J Biol Chem* 278 (31), 28976-84.
124. Penengo, L. et al. (2006) Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin. *Cell* 124 (6), 1183-95.
125. Hirano, S. et al. (2006) Double-sided ubiquitin binding of Hrs-UIM in endosomal protein sorting. *Nat Struct Mol Biol* 13 (3), 272-7.
126. Hong, Y.H. et al. (2009) Identification of a novel ubiquitin binding site of STAM1 VHS domain by NMR spectroscopy. *FEBS Lett* 583 (2), 287-92.
127. Bilodeau, P.S. et al. (2004) The GAT domains of clathrin-associated GGA proteins have two ubiquitin binding motifs. *J Biol Chem* 279 (52), 54808-16.
128. Kawasaki, M. et al. (2005) Molecular mechanism of ubiquitin recognition by GGA3 GAT domain. *Genes Cells* 10 (7), 639-54.
129. Akutsu, M. et al. (2005) Structural basis for recognition of ubiquitinated cargo by Tom1-GAT domain. *FEBS Lett* 579 (24), 5385-91.
130. Wang, B. et al. (2003) Structure and ubiquitin interactions of the conserved zinc finger domain of Npl4. *J Biol Chem* 278 (22), 20225-34.
131. Reyes-Turcu, F.E. et al. (2006) The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. *Cell* 124 (6), 1197-208.
132. Pai, M.T. et al. (2007) Solution structure of the Ubp-M BUZ domain, a highly specific protein module that recognizes the C-terminal tail of free ubiquitin. *J Mol Biol* 370 (2), 290-302.
133. Bomar, M.G. et al. (2007) Structure of the ubiquitin-binding zinc finger domain of human DNA Y-polymerase eta. *EMBO Rep* 8 (3), 247-51.
134. Rizzo, A.A. et al. (2014) NMR structure of the human Rad18 zinc finger in complex with ubiquitin defines a class of UBZ domains in proteins linked to the DNA damage response. *Biochemistry* 53 (37), 5895-906.
135. Husnjak, K. et al. (2008) Proteasome subunit Rpn13 is a novel ubiquitin receptor. *Nature* 453 (7194), 481-8.
136. Hirano, S. et al. (2006) Structural basis of ubiquitin recognition by mammalian Eap45 GLUE domain. *Nat Struct Mol Biol* 13 (11), 1031-2.
137. Alam, S.L. et al. (2006) Structural basis for ubiquitin recognition by the human ESCRT-II EAP45 GLUE domain. *Nat Struct Mol Biol* 13 (11), 1029-30.
138. Teo, H. et al. (2004) Structural insights into endosomal sorting complex required for transport (ESCRT-I) recognition of ubiquitinated proteins. *J Biol Chem* 279 (27), 28689-96.
139. Sundquist, W.I. et al. (2004) Ubiquitin recognition by the human TSG101 protein. *Mol Cell* 13 (6), 783-9.
140. Bellare, P. et al. (2006) Ubiquitin binding by a variant Jab1/MPN domain in the essential pre-mRNA splicing factor Prp8p. *RNA* 12 (2), 292-302.
141. Mullally, J.E. et al. (2006) Doa1 is a Cdc48 adapter that possesses a novel ubiquitin binding domain. *Mol Cell Biol* 26 (3), 822-30.
142. Stamenova, S.D. et al. (2007) Ubiquitin binds to and regulates a subset of SH3 domains. *Mol Cell* 25 (2), 273-84.

143. Ortega Roldan, J.L. et al. (2013) Distinct ubiquitin binding modes exhibited by SH3 domains: molecular determinants and functional implications. *PLoS One* 8 (9), e73018.
144. Rahighi, S. et al. (2009) Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. *Cell* 136 (6), 1098-109.
145. Nicholson, B. et al. (2014) Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives. *J Biomol Screen* 19 (7), 989-99.
146. Lindner, S. and Kronke, J. (2016) The molecular mechanism of thalidomide analogs in hematologic malignancies. *J Mol Med (Berl)* 94 (12), 1327-1334.
147. Liu, Y. et al. (2015) A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. *FASEB J* 29 (12), 4829-39.
148. Lu, G. et al. (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science* 343 (6168), 305-9.
149. Kronke, J. et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science* 343 (6168), 301-5.
150. Donovan, K.A. et al. (2018) Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. *Elife* 7.
151. Matyskiela, M.E. et al. (2018) SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. *Nat Chem Biol* 14 (10), 981-987.
152. Sasaki, Y. et al. (2013) Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells. *EMBO J* 32 (18), 2463-76.
153. Sims, J.J. et al. (2012) Polyubiquitin-sensor proteins reveal localization and linkage-type dependence of cellular ubiquitin signaling. *Nat Methods* 9 (3), 303-9.
154. Moutel, S. et al. (2016) NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. *Elife* 5.

A

Tag His, HA, FLAG, Myc

Tag AviTag

Tag Biotin

Tag Streptavidin

Tag Tag-specific antibodies

Tag Different UbL-specific antibodies

Tag TUBEs, SUBES, mixed chain-specific binding entities

Tag Affimers

Tag Nanobodies

Tag Minibodies

B

Advantages

Disadvantages

TUBEs and anti GG antibody

- Protection of ubiquitin chains (TUBE-protection effect).
- Enrichment of all ubiquitin GG signatures

- Antibodies provide MS background
- Hybrid chains can provide GG signatures for other UbLs

TUBEs and affimers

- TUBE-protection effect
- Enrichment of ubiquitin linkage specific GG signatures
- No GG signatures for other UbLs

- Big tags provide MS background
- Method to be implemented

TUBEs and aptamers

- TUBE-protection effect
- Enrichment of ubiquitin linkage specific GG signatures
- No GG signatures for other UbLs

- Big tags provide MS background
- Method to be implemented

A Detection

SPR
Calorimetry
Thermophoresis

Western blot

Fluorescence

B Identification

Western blot

Mass Spectrometry

TUBEs' Applications

C Quantification & Characterization

HTS techniques

UbiTest assay

Homogeneous TUBE-AlphaLisa assay

Heterogeneous TUBE-DELFI assay

Ubiquitin array